Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
about
Novel strategies to target the ubiquitin proteasome system in multiple myelomaTargeting the ubiquitin pathway for cancer treatmentClinical use of proteasome inhibitors in the treatment of multiple myelomaTreatment of multiple myeloma bone disease: experimental and clinical data.Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer CellsMisfolded proteins: from little villains to little helpers in the fight against cancer.The use of novel agents in multiple myeloma patients with hepatic impairment.Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosisTargeting ubiquitination for cancer therapies.Carfilzomib in multiple myeloma.SCF ubiquitin ligase-targeted therapies.When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.Targeted Covalent Inhibitors for Drug Design.Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Proteasome inhibition by bortezomib: A left hook and a right punchIt's all about talking: two-way communication between proteasomal and lysosomal degradation pathways via ubiquitin.Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.The Proteasome and Myeloma-Associated Bone Disease.Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
P2860
Q26773246-56C268F7-035F-403A-8488-B46B94804F1FQ26866185-0CFC0F87-6A70-4C53-BFC0-120D39C7567FQ28080999-DA11C05B-42CB-4A05-ACFB-4C09418B70D4Q30868833-F328A975-6E94-4476-8C2C-3902D32CA702Q33624386-3A3116B3-5286-41D0-A01A-2813E78B279FQ34466592-BC356641-8A3D-427F-8F2A-38C1DF447B5EQ35182819-CD0DFC39-93D9-4BBC-A39C-C5E2B70A2BAEQ36893329-CF14AA32-C077-4BA2-ACF4-0EDC4521041EQ36928677-FF442F3C-619E-4CF8-BF05-590A6722CF6DQ37158445-F70E3FA2-D0BB-4D4C-9254-24C081191011Q38244558-D48E60A8-02D2-438F-9812-759D6199468FQ38267996-9300160D-A750-4829-BD67-3DC25BFB4229Q38503345-41C53FFF-3FAC-422A-A28D-7E32EEE2DCDBQ38882295-19CCF340-B5B6-4B97-B6A6-0A8D1127403EQ38931379-6F0403AC-92D9-4F93-A2F7-553F76FF91FAQ38959241-B7B4D327-2F60-4948-A4A3-4D9113FEFDEAQ39135493-F42287F8-CC13-46B9-9979-8FEB7F6B12DAQ39234159-88E92EDE-96D9-4E26-ADD6-DF849BF2A846Q42001818-9699E8E0-FFA9-4171-99A4-E13A62B31656Q42361268-DA548E93-4171-42C9-9EE3-085F3924A149Q47631097-AEA265CE-D47D-415C-A562-7FC17974E57DQ47696279-609021C7-7706-43AA-AA09-3A8FFC37A626Q51504147-8259A829-E35A-40AC-BB8E-6AC83F7CEFE2Q52597827-512C2314-A39A-497A-9F8D-0BDCEFE966BAQ53800155-F4C7B2D6-E38D-48CA-97FD-0EAEEF3D7CD1Q55642634-BB91505B-129D-4DDA-AF52-D28B444BC31FQ56362782-BA72305D-8283-45FB-9FEB-2501F3171A36
P2860
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
@en
type
label
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
@en
prefLabel
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
@en
P2093
P2860
P921
P356
P1476
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
@en
P2093
Lenka Kubiczkova
Ludek Pour
Sabina Sevcikova
P2860
P304
P356
10.1111/JCMM.12279
P5008
P577
2014-04-08T00:00:00Z
2014-06-01T00:00:00Z